Explain the Role of Vilobelimab, the Latest MAb for COVID-19
June 2023
A new emergency use authorization will put the spotlight on vilobelimab (Gohibic) to treat COVID-19 in hospitalized adults.
Vilobelimab blocks complement C5a...to reduce inflammation.
It’s only authorized to treat COVID-19 when started within 48 hours after beginning mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote